Efficacy News and Research

RSS

Prasugrel as safe as clopidogrel in preventing heart attack, stroke and death

The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs - prasugrel and clopidogrel - in preventing the first occurrence of death, heart attack or stroke, according to Duke University Medical Center cardiologists.

27 Aug 2012

Research roundup: Who do patients seek for primary care?; Treating kids with antipsychotics

n order to find out what kind of doctor patients were visiting for primary care service, researchers analyzed the frequency in which patients visited generalists and specialists in 1999 and 2007 by using a nationally representative sample of outpatient visits.

26 Aug 2012

Trevo Retriever effectively removes blood clots in patients with stroke

Every 40 seconds, someone in the United States has a stroke, usually caused when a clot blocks an artery that supplies blood to the brain. Now the results of two multicenter studies published online in The Lancet on August 26 are giving physicians new innovative tools proven to better remove these clots that block blood flow.

26 Aug 2012

Vandetanib shows efficacy in thyroid cancer

The tyrosine kinase inhibitor vandetanib could significantly extend progression-free survival in patients with locally advanced or metastatic differentiated radioiodine-refractory thyroid cancer, show results of a small phase II randomized trial.

24 Aug 2012

Dartmouth’s professor shares news of DAR-901 TB vaccine development

Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide attributable to a single infectious agent, according to the World Health Organization (WHO). With 8.8 million cases in 2010 and 95 percent of TB deaths occurring in low- and middle-income countries, the disease continues to be a major public health problem in the developing world. In a July address to the International Union Against Tuberculosis and Lung Disease, Dartmouth's C. Fordham (Ford) von Reyn shared news of a promising vaccine in the works.

24 Aug 2012

Study demonstrates how DBP production is modulated by daily variations of temperature

Numerous processes in our body fluctuate in a regular pattern during the day. These circadian (or daily) variations can be driven by local oscillators present within our cells or by systemic signals controlled by the master pacemaker, located in the brain. Ueli Schibler, professor at the University of Geneva (UNIGE), Switzerland, unveils a molecular mechanism by which body temperature rhythms influence the expression of 'clock genes' and synchronize local oscillators.

24 Aug 2012

Nanoparticle may bring great benefits to emergency treatment of brain-injury victims

A nanoparticle developed at Rice University and tested in collaboration with Baylor College of Medicine (BCM) may bring great benefits to the emergency treatment of brain-injury victims, even those with mild injuries.

24 Aug 2012

AcelRx commences third ARX-01 Phase 3 study in post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced dosing of the first patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia (PCA) system.

24 Aug 2012

Fizzy tablet is best method to receive fentanyl for cancer pain

Results of a mixed treatment comparison show that fentanyl in the form of an effervescent buccal tablet can better relieve the intensity of breakthrough cancer pain in the first 60 minutes after dosing compared with other fentanyl formulations.

23 Aug 2012

Positron submits Drug Master File with FDA for production of API grade Sr-82

Positron Corporation, a leading molecular imaging healthcare company, is pleased to announce the submission of a Drug Master File (DMF), with the Federal Drug Administration (FDA), for the production of Active Pharmaceutical Ingredient (API) grade strontium-82, through its wholly owned subsidiary Manhattan Isotope Technology, LLC.

23 Aug 2012

Aeras, IDRI announce start of first ID93 + GLA-SE Phase I trial for tuberculosis

Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE.

23 Aug 2012

Laminin-111 protein therapy could treat Duchenne muscular dystrophy

A novel treatment in development at the University of Nevada School of Medicine for the most common form of muscular dystrophy is advancing towards human trials with a $308,000 boost from the Muscular Dystrophy Association.

23 Aug 2012

Spicy solution for viral infection

Curcumin, the main compound in the spice turmeric, prevents replication of mosquito-borne Rift Valley Fever virus in infected cells, report researchers.

22 Aug 2012

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

The hematology journal BLOOD published today a full-length article describing final Phase 2 data for Symphogen's rozrolimupab, a novel human recombinant mixture of 25 antibodies which all are manufactured simultaneously from a single batch.

22 Aug 2012

NIAID announces 14 grants for basic research to identify new HIV vaccine approaches

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine.

22 Aug 2012

GM-CSF depletion suppresses pain in people with arthritis-related conditions

The research relates to a family of molecules firstly discovered in Melbourne that applied to blood cell development. One of these, granulocyte macrophage colony-stimulating factor or GM-CSF, acts as a messenger between cells acting at a site of inflammation.

22 Aug 2012

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has initiated dosing in a multicenter (USA), randomized, placebo and active comparator controlled Phase 2b study that will enroll approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% - 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea.

22 Aug 2012

Vitamin D may help fight childhood acute respiratory infections

Supplementation with vitamin D, particularly in winter, appears to reduce a child’s risk for contracting acute respiratory infections by almost 50%, show results from a Mongolian study.

21 Aug 2012

Tips for menopause symptom relief

An estimated 6,000 women in the U.S. reach menopause every day (about two million annually).The most common menopausal complaints include hot flashes, sleep disturbances, anxiety, poor mood, and physical and mental exhaustion. Hot flashes affect 80 percent of peri- or postmenopausal women, with 30 percent reporting hot flashes severe enough to seriously affect their quality of life.

21 Aug 2012

Bile duct cancer chosen as next indication for PCI Biotech

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has chosen bileduct cancer as the next indication for the use of its PCI (photochemical internalisation) localised cancer therapy. In this indication PCI Biotech’s proprietary photosensitiser Amphinex® will be used in combination with the generic cytotoxic agent gemcitabine. The aim is to start the clinical Proof of Concept study within end of 1H 2013.

21 Aug 2012